Sildenafil citrate–loaded targeted nanostructured lipid carrier enhances receptivity potential of endometrial cells via LIF and VEGF upregulation
- 13 September 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Naunyn-Schmiedebergs Archiv für experimentelle Pathologie und Pharmakologie
- Vol. 394 (11), 2323-2331
- https://doi.org/10.1007/s00210-021-02153-8
Abstract
The main objective of this research is to prepare sildenafil citrate (SC)–loaded arginyl-glycyl-aspartic acid (RGD)–containing nanostructured lipid carrier (SC-loaded NLC-RGD) and evaluate their effects on the receptivity potential of endometrial cells. Hot homogenization method was used to prepare SC-loaded NLC-RGD. Then, size, drug encapsulation, and morphology of prepared nanoparticles were studied by photon correlation spectroscopy technic, ultrafiltration method, and scanning electron microscopy, respectively. Subsequently, the influence of SC-loaded NLC-RGD on endometrial receptivity was evaluated by in vitro implantation assay. Finally, expression of vascular endothelial growth factor (VEGF), leukemia inhibitory factor (LIF), and integrin beta 3 (as endometrial receptivity markers) was assessed in SC-loaded NLC-RGD-treated endometrial cells by reverse transcription polymerase chain reaction (RT-PCR). Particles with a nano-size diameter (92.7 nm), appropriate polydispersity index (0.21), spherical morphology, and acceptable loading efficiency were prepared. In vitro implantation assay showed that SC, SC-loaded NLC, and SC-loaded NLC-RGD improve the rate of endometrial attachment potential by 1.6 ± 0.4, 1.7 ± 0.3, and 2.3 ± 0.3 times, respectively. Analysis of RT-PCR results showed the enhancing mRNA of LIF and VEGF in SC-treated endometrial cells. Results also confirmed the higher influence of SC-loaded NLC-RGD on gene expression patterns in comparison to SC. Using NLC-RGD as a carrier to deliver SC to endometrial cells is an effective approach to improve endometrial receptivity. Upregulation of LIF and VEGF is the probable mechanism by which SC enhances the endometrial receptivity potential.Keywords
This publication has 37 references indexed in Scilit:
- Sildenafil citrate improves perinatal outcome in fetuses from pre‐eclamptic ratsBJOG: An International Journal of Obstetrics and Gynaecology, 2012
- Solid lipid nanoparticles as intracellular drug transporters: An investigation of the uptake mechanism and pathwayInternational Journal of Pharmaceutics, 2012
- Sildenafil citrate therapy for severe early-onset intrauterine growth restrictionBJOG: An International Journal of Obstetrics and Gynaecology, 2011
- Is sildenafil citrate affect endometrial receptivity? an immunohistochemical studyGynecological Endocrinology, 2010
- Endometrial growth and uterine blood flow: a pilot study for improving endometrial thickness in the patients with a thin endometriumFertility and Sterility, 2010
- Sildenafil Increases Uterine Blood Flow in Nonpregnant Nulliparous WomenReproductive Sciences, 2010
- Sildenafil citrate improves fetal outcomes in pregnant, l-NAME treated, Sprague–Dawley ratsEuropean Journal of Obstetrics & Gynecology and Reproductive Biology, 2009
- Endometrial receptivity markers, the journey to successful embryo implantationHuman Reproduction Update, 2006
- Expression of phosphodiesterase 5 in maternal and fetal sheepAmerican Journal of Obstetrics and Gynecology, 2005
- Modulation of surface charge, particle size and morphological properties of chitosan–TPP nanoparticles intended for gene deliveryColloids and Surfaces B: Biointerfaces, 2005